CSPC received a USD 30 million upfront payment from AstraZeneca on Aug. 12 under an siRNA collaboration, option, and license deal.
Funding supports development of small nucleic acid drug candidates using CSPC’s proprietary siRNA discovery platform with extrahepatic targeted delivery technology.
Payment follows the agreement announced on July 2, 2026, signaling continued progress in the strategic R&D collaboration.
AZN•
